Literature DB >> 31838173

Isolation and characterization of a variant subgroup GII-a porcine epidemic diarrhea virus strain in China.

Dan Yang1, Mingjun Su1, Chunqiu Li1, Bei Zhang1, Shanshan Qi1, Dongbo Sun2, Baishuang Yin3.   

Abstract

BACKGROUND: Highly virulent variants of porcine epidemic diarrhea virus (PEDV) have been closely associated with recent outbreaks of porcine epidemic diarrhea (PED) in China, which have resulted in severe economic losses to the pork industry.
METHODS: In the current study, the variant PEDV strain HM2017 was isolated and purified and a viral growth curve was constructed according to the median tissue culture infective dose (TCID50). HM2017 were amplify with RT-PCR and analyzed by phylogeny analysis. Animal pathogenicity experiment was carried to evaluate the HM2017 clinical assessment.
RESULTS: Genome-based phylogenetic analysis revealed that PEDV strain HM2017 was clustered into the variant subgroup GII-a that is currently circulating in pig populations in China. The highest median tissue culture infectious dose of strain HM2017 after 15 passages in Vero cells was 1.33 × 107 viral particles/mL. Strain HM2017 was highly virulent to suckling piglets, which exhibited clinical symptoms at 12 h post-infection (hpi) (i.e., weight loss at 12-84 hpi, increased body temperatures at 24-48 hpi, high viral loads in the jejunum and ileum, and 100% mortality by 84 hpi).
CONCLUSION: The present study reports a variant subgroup GII-a PEDV HM2017 strain in China and characterize its pathogenicity. PEDV strain HM2017 of subgroup GII-a presents a promising vaccine candidate for the control of PED outbreaks in China.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Pathogenicity; Porcine epidemic diarrhea virus; Vaccine; Variant strain

Year:  2019        PMID: 31838173     DOI: 10.1016/j.micpath.2019.103922

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

1.  Novel Method for Isolation of Porcine Epidemic Diarrhea Virus with the Use of Suspension Vero Cells and Immunogenicity Analysis.

Authors:  Fei-Fei Ge; De-Quan Yang; Xin Li; Hou-Bin Ju; Hai-Xiao Shen; Jian Liu; Hong-Jin Zhao; Jian Wang
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

2.  Coronavirus Porcine Epidemic Diarrhea Virus Nucleocapsid Protein Interacts with p53 To Induce Cell Cycle Arrest in S-Phase and Promotes Viral Replication.

Authors:  Mingjun Su; Da Shi; Xiaoxu Xing; Shanshan Qi; Dan Yang; Jiyu Zhang; Yuru Han; Qinghe Zhu; Haibo Sun; Xiaoran Wang; Haoyang Wu; Meijiao Wang; Shan Wei; Chunqiu Li; Donghua Guo; Li Feng; Dongbo Sun
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

3.  Epidemic and Evolutionary Characteristics of Swine Enteric Viruses in South-Central China from 2018 to 2021.

Authors:  Chang Li; Hongyu Lu; Chao Geng; Keli Yang; Wei Liu; Zewen Liu; Fangyan Yuan; Ting Gao; Shuangshuang Wang; Ping Wen; Haofei Song; Yongxiang Tian; Danna Zhou
Journal:  Viruses       Date:  2022-06-28       Impact factor: 5.818

4.  Molecular Characterization and Phylogenetic Analysis of a Variant Recombinant Porcine Epidemic Diarrhea Virus Strain in China.

Authors:  Xiaoliang Hu; Yuexiao Lian; Yucan He; Xiangxiao Liu; Zhige Tian; Yi Dai; Mengyuan Liu; Huayan Fan; Yue Shi; Feng Cong
Journal:  Animals (Basel)       Date:  2022-08-25       Impact factor: 3.231

5.  Development and Application of a Reverse-Transcription Recombinase-Aided Amplification Assay for Porcine Epidemic Diarrhea Virus.

Authors:  Xiuhong Wu; Yuanjia Liu; Liguo Gao; Zhuanqiang Yan; Qiqi Zhao; Feng Chen; Qingmei Xie; Xinheng Zhang
Journal:  Viruses       Date:  2022-03-12       Impact factor: 5.048

6.  Genetic Characteristics and Pathogenicity of a Novel Porcine Epidemic Diarrhea Virus with a Naturally Occurring Truncated ORF3 Gene.

Authors:  Yuan-Hang Zhang; Hong-Xuan Li; Xi-Meng Chen; Liu-Hui Zhang; You-Yi Zhao; Ai-Fang Luo; Yu-Rong Yang; Lan-Lan Zheng; Hong-Ying Chen
Journal:  Viruses       Date:  2022-02-27       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.